WHO pandemic treaty
After more than three years of complex and sometimes contentious negotiations, the WHO countries have successfully struck a deal to establish a comprehensive pandemic treaty aimed at addressing the severe inadequacies exposed during the Covid-19 crisis.
This agreement must be welcomed, as it lays a necessary foundation for greater global cooperation, preparedness, and equitable access to healthcare resources in future global health emergencies.
Central to the treaty is the introduction of the Pathogen Access and Benefit-Sharing System (PABS). This innovative mechanism is designed to streamline the rapid sharing of pathogen-related data with pharmaceutical firms, expediting the development and distribution of vaccines, diagnostics, and therapeutics.
By committing to this level of transparency and cooperation, the treaty directly addresses one of the greatest failures of the global response to Covid-19—the slow and uneven distribution of crucial medical resources. Ensuring that medical breakthroughs swiftly translate into universally accessible healthcare solutions is undoubtedly one of the treaty's most commendable components.
Another notable achievement of the agreement is its nuanced approach towards technology transfers. Technology transfer, particularly concerning pharmaceutical products developed during pandemics, has historically been a sticking point, with powerful pharmaceutical interests often prioritising intellectual property rights above public health needs.
The finalised text of the treaty states that such transfers must be 'mutually agreed,' thereby finding a pragmatic balance between protecting intellectual property and facilitating widespread access to essential health technologies. While this compromise may not satisfy all stakeholders fully, it is a significant step forward, showing that member states recognise the imperative of balancing commercial interests with public health necessities.
Additionally, the treaty contains a pivotal commitment by pharmaceutical manufacturers to allocate 20 percent of their real-time pandemic-related production to WHO-coordinated efforts. This clause directly addresses the stark inequities witnessed during the Covid-19 vaccine rollout, where wealthy nations secured large portions of early vaccine supplies, leaving many developing countries dangerously exposed.
This structured allocation will play a vital role in ensuring equitable access, offering a degree of protection against vaccine nationalism and commercial exploitation in future crises.
Despite its evident strengths, though, the treaty is not without challenges. Most notably, the absence of the United States, following its announced departure from the WHO, significantly undermines the treaty's global reach and effectiveness.
American participation and leadership have historically played key roles in international health responses. Without US involvement, there remains a potential gap in implementation and financing, as well as uncertainty regarding global leadership in health crises.
The true test of this agreement, however, will come in its practical implementation. Member states must not only ratify, but actively enforce and operationalise its provisions. Adequate funding, political commitment, and sustained global solidarity are crucial if the treaty is to transcend symbolic significance and achieve practical effectiveness. It will require governments to look beyond immediate national interests and embrace a genuinely cooperative stance on global health.
In welcoming this treaty, it is vital to recognise that pandemics are not isolated health events; they are global phenomena requiring robust, collective responses. This landmark agreement signifies a strong international consensus on the necessity of preparedness, equity, and transparency in managing future pandemics.
However, the real work begins now. The international community must remain vigilant and committed to ensuring that these ambitious aspirations translate into concrete actions, safeguarding humanity's collective health and well-being in the years to come.
Copyright Business Recorder, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Recorder
3 days ago
- Business Recorder
Challenge of cancer treatment, prevention
EDITORIAL: Recently, Pakistan has launched two significant public health partnership initiatives aimed at tackling cancer prevention and treatment. First, just a few days ago, the Federal Ministry of Health signed an agreement with the World Health Organisation (WHO) to participate in the Global Platform for Access to Child Cancer. This programme is designed to improve the availability and accessibility of lifesaving treatments for children battling cancer. With approximately 8,000 children diagnosed each year, this collaboration is expected to make a profound difference in the lives of young patients and their families. In addition, the Gates Foundation has announced plans to begin rolling out cervical cancer vaccinations next month. According to a senior official from the Foundation's Gender Equity Division, the initial phase will target girls aged 9 to 11, with the eventual goal of extending the vaccine to older girls and women. Access to both cancer treatment and prevention remains a critical challenge in many parts of the world, particularly in developing countries like Pakistan, where the cost of treatment can be prohibitively high for most families. In many low- and middle-income countries, the lack of affordable healthcare is one of the leading reasons behind the significantly lower cancer survival rates. In Pakistan, for instance, the current survival rate for children with cancer stands at just 30 percent, far below the 80 percent survival rate found in high-income countries. However, the federal Ministry of Health has expressed hope that by 2030, the survival rate for children in Pakistan could rise to 60 percent. That though is possible only if access to quality treatment becomes more widespread and affordable. Our participation in the Global Platform for Access to Child Cancer represents a vital opportunity for thousands of families who would otherwise be unable to afford such treatments. While providing free medicines is an essential step, it's equally crucial to raise public awareness about these resources. Effective communication is needed so that families in need can fully benefit from the available support. Turning to the second initiative, the HPV vaccine has already been successfully introduced in 25 African countries with the support of Gavi, the Vaccine Alliance — a public-private global health partnership. This initiative has saved millions of lives by preventing cervical cancer, a disease that disproportionately affects women in low- and middle-income countries. Undoubtedly, the HPV vaccine is one of the most effective methods for reducing cervical cancer incidence; it should be integrated into Pakistan's national vaccination programme, focusing initially on girls and young women. The success of HPV vaccination, along with the provision of quality-assured, free medicines — procured and distributed by UNICEF — could dramatically increase the survival rate of children diagnosed with cancer. The successful implementation of similar initiatives in other parts of the world highlights the potential impact of collaborative efforts between governments, international organisations, and health initiatives to combat preventable diseases. By replicating these programmes, Pakistan could make significant progress in cancer prevention and treatment, saving thousands of lives. Copyright Business Recorder, 2025
Express Tribune
4 days ago
- Express Tribune
HPV vaccine to roll out in Sindh, addressing technical but not social gaps
The human papillomavirus (HPV) vaccine to prevent cervical cancer will be rolled out from September 15 in Sindh, with health officials warning that community mistrust, persistent rumours and gaps in vaccinator training could undermine the campaign. Around 50% of the target group is enrolled in schools, with coordination underway [between health officials and the] education department to facilitate in-school vaccinations, said Dr Rehan Baloch, speaking at the Globe HPV Seminar at Aga Khan Univeristy (AKU). 'We have earmarked around Rs 200 million for the HPV vaccine, with additional support from Gavi and other partners for advocacy and outreach,' he said, stressing the need for stronger engagement with parents, teachers and healthcare providers. The campaign will rely on paediatricians, gynaecologists and frontline workers to inform communities about HPV and cervical cancer prevention. Photo Courtesy: AKU Sindh Expanded Programme on Immunisation (EPI) Project Director Dr Raj Kumar described the rollout as a 'historic initiative' and said preparations were focused on operational logistics and microplanning at the union council level, drawing on experience from measles, typhoid and polio campaigns. Officials said 20 million girls aged nine to 14 are registered in schools nationwide, with the remainder out of school. An estimated 70% of vaccinations will take place in schools and the rest are to be administered in community settings through partnerships with public and private sectors. What is HPV? Cervical cancer kills more than 300,000 women worldwide each year, with the heaviest death toll in low- and middle-income countries. In Pakistan, the disease is among the leading cancers in women and is often diagnosed too late, despite being largely preventable through timely vaccination. The human papillomavirus (HPV) — a sexually transmitted infection — is responsible for 91% of cervical cancers globally. According to the World Health Organization (WHO), more than 291 million women are diagnosed annually and about 340,000 die from the disease, most in countries like Pakistan. Recent estimates indicate that every year in Pakistan, 5,008 women are diagnosed with cervical cancer and 3,197 die from the disease, according to the Human Papillomavirus and Related Cancers, Fact Sheet 2023. HPV has over 200 known types, classified into low-risk and high-risk categories. While most low-risk infections are asymptomatic and resolve on their own, high-risk strains HPV 16 and 18 are linked to 70–80% of cervical cancer cases. In Pakistan, nine out of 10 cases are caused by these two strains. The country reports about 5,000 new cases and 3,000 deaths each year, with 73–74 million women at risk. The HPV vaccine is most effective for girls aged nine to 14, but coverage is hindered by data gaps, slow rollout and social barriers. Pakistan's age-standardised incidence rate is 6.1 per 100,000 women — above the WHO's recommended threshold of four or fewer. The WHO's 2020 global strategy calls for vaccinating 90% of girls in this age group by 2030, but global uptake remains below 15% due to delays in national programmes. The Zekolin vaccine being introduced in Pakistan protects against HPV types 16 and 18, which modelling by the International Agency for Research on Cancer (IARC) suggests could prevent up to 83% of cervical cancer cases in the Eastern Mediterranean, Central, Western, and Southern Asia. Newer-generation vaccines covering multiple HPV types could increase protection to 95%. Top down approach vs community-led engagement The HPV campaign's success in Sindh will depend not only on logistics but also on addressing deep-rooted social inequities. A technical, top-down approach risks alienating communities already excluded from decision-making, underscoring the need for participatory strategies that treat local populations as equal partners in health initiatives. Pakistan's entrenched health and education inequalities cannot be resolved by technical fixes alone, warned Dr Kausar S Khan, a public health researcher and human rights activist, calling for participatory action research and community-led engagement as the foundation of social policy. The country's policy and academic elite — researchers, senior bureaucrats and service providers — form a small, privileged minority, while 'the poor, women, minorities, transgender people, and those with different sexual orientations' make up the majority yet remain excluded from decision-making, stressed Dr Khan. 'In Karachi, more than 50% of the population lives in kachhi abadis without water, electricity, or sanitation — and yet we want to take science to them,' she said, warning that a science-heavy, top-down approach ignores participatory ethics and local realities. Drawing from her work in participatory action research, Dr Khan urged a 'power-based, strength-based approach' that begins with 'knowing yourself' and treating communities as equal partners rather than passive recipients of awareness campaigns by focusing on women development department for HPV vaccination initiatives. This, she underscored, is lacking in the campaign. However, the assumption that vaccines and other technical interventions can address deep-rooted social problems is incorrect. 'The successes we see are technical. But the social side is where it was,' she said, stressing that performance indicators and programmatic processes cannot replace genuine community inclusion. Gaps and awareness Awareness of cervical cancer and the human papillomavirus (HPV) in Pakistan remains alarmingly low, with entrenched cultural norms and gender dynamics posing major challenges to HPV vaccine uptake, according to findings from the JPEGOS CAHPS study presented by UNICEF's Social and Behavioral Change (SBC) team. The study found that only 17.2% of respondents were aware of cervical cancer, a mere 4.4% of caregivers had heard of HPV, and only 2.9% knew of the HPV vaccine's existence. UNICEF officials said the fear of cancer could be a motivator, but misconceptions about hygiene, fatalistic beliefs, and women's limited role in healthcare decision-making severely hinder acceptance. Language and framing were found to influence perceptions — 'vaccine' evoked hope and prevention for adolescent girls, while 'injection' triggered a fear of needles and illness. UNICEF's co-creation sessions emphasised portraying girls as aspirational subjects rather than vulnerable objects, and using images that reflect real communities instead of idealised versions. Awareness about the HPV vaccine is particularly low, with 95% of people surveyed having never heard of it. However, trust in official guidance is high — 90% said they would accept the vaccine if recommended by the government, a doctor, or religious leaders. Around 76–81% expressed interest in cervical cancer or HPV screening, and 79–80% said they would vaccinate themselves or their daughters. Barriers include access to vaccines, family objections, minor fears about pain or side effects, cost concerns, and embarrassment due to misconceptions about the vaccine's necessity. Reluctance is notably higher among mothers than daughters. Mothers emerged as the key gatekeepers for consent, due to their close communication with daughters, while fathers — often uninvolved in daily health decisions — hold passive approval that can stall campaigns. 'In fact, mothers who exhibited a greater knowledge of cervical cancer showed a more [bigger] risk of not wanting to vaccinate their daughters compared to those who had never heard of it,' noted Dr Fyezah Jehan, Professor and Chair at AKU. 'It is trust and reassurance, and addressing these concerns, that will allow us to manage it better.' She added that acceptance is highest when mothers understand both the benefits and the safety of the vaccine, without having general concerns about childhood immunisation. Social listening efforts by UNICEF and other partners are underway to identify local concerns and adapt communication strategies to build vaccine confidence and prevent hesitancy. Findings indicate that both parents and health workers require targeted engagement. 'We need to convince our vaccinators, our health workers even more that this vaccine is good, and then they will transmit that confidence…to the communities and the key stakeholders,' said Dr Paul Bloem, WHO HPV Vaccine Senior Technical Officer, stressing the need for continuous training to reinforce trust. Despite strong safety data, rumours persist, particularly claims linking the vaccine to infertility. The global vaccine safety committee has repeatedly reviewed such allegations and found 'no association between HPV vaccination and infertility'. Experts note the vaccine may actually help prevent infections that can reduce fertility. Evidence from other countries, such as Bangladesh, shows that careful preparation and adopting a one-dose strategy can achieve national coverage rates above 90% at launch. Officials warn that without similar groundwork in Pakistan, achieving high coverage from the outset — critical for long-term success — will remain out of reach.
Business Recorder
08-08-2025
- Business Recorder
Better access to childhood cancer treatment
EDITORIAL: Pakistan has recently signed an agreement with the World Health Organisation (WHO) to participate in the Global Platform for Access to Childhood Cancer, an initiative designed to enhance the availability and accessibility of life-saving treatments for children battling cancer. With approximately 8,000 children diagnosed annually, this agreement is expected to have a significant impact on the lives of young patients and their families. At the signing event, WHO Representative in Pakistan, Dr Dapeng Luo, emphasised the importance of the collaboration with the Ministry of Health and other partners, including UNICEF — which will be responsible for the procurement and distribution of medicines — adding that 'no child is to be left behind, no matter where they live or who they are.' One of the most encouraging aspects of this agreement is the provision of quality-assured, free medicines, which could greatly increase the survival rate of children diagnosed with cancer. Access to cancer treatment, particularly for paediatric patients, remains a critical challenge in many parts of the world, especially in developing countries like Pakistan, where the cost of treatment can be prohibitively high for most families. In many countries, the lack of affordable healthcare is one of the primary reasons behind significantly lower cancer survival rates. In Pakistan, for instance, the current survival rate for children with cancer, as per official figures, stands at 30 percent, far below the 80 percent survival rate in high-income countries. The federal health ministry has expressed the hope that by 2030 the survival rate for children in Pakistan could increase to 60 percent. That is possible only if access to quality treatment becomes more widespread and affordable. Our participation in the Global Platform represents a vital opportunity for thousands of families who would otherwise be unable to afford cancer treatment. However, along with the provision of free medicines, it is essential to raise public awareness about the availability of these resources. The new initiative must be effectively communicated so that families in need can take full advantage of its support. There are other successful public health initiatives that Pakistan can learn from. In Africa, for example, 25 countries have introduced the HPV vaccine for cervical cancer prevention with the support of Gavi, the Vaccine Alliance — a public-private global health partnership. It has saved millions of lives by preventing cervical cancer, a disease that disproportionately affects women in low- and- middle-income countries. HPV vaccination has proven to be one of the most effective ways for reducing the incidence of cervical cancer. Pakistan should also seriously consider integrating the HPV vaccine into its national vaccination programme, focusing on girls and young women. The success of the HPV vaccination initiative in Africa serves as a powerful example of what can be achieved when governments, international organisations, and health initiatives work together to tackle preventable diseases. By replicating such programmes, Pakistan can make significant strides in cancer prevention and treatment, potentially saving thousands of lives. Copyright Business Recorder, 2025
